Anocca was founded in 2014 to build biotechnologies, processes and infrastructure needed to decode T-cell immunity, with the ambition to build new forms of T-cell immunotherapies. During the past decade we've invented, refined and deployed technologies and infrastructure into a deep tech platform to analyse T-cell biology at scale. Today we focus on the development and manufacturing of libraries of TCR-T cell therapies for the hardest to treat cancers.  

We are more than 100 scientists, software developers, engineers, manufacturing and quality specialist, and dedicated support and business personnel working out of state-of-the-art facilities in Sweden

large_map_about_us.png

medium_map_about_us.png

small_map_about_us.png

thumbnail_map_about_us.png

map_about_us.png

We’ve assembled a talented multidisciplinary team from all over the globe. Hailing from over 35 different nations, we bring together the diverse talent and perspectives needed to create our unique platform company and to deliver on our vision to decode T-cell immunity and engineer powerful T-cell immunotherapies.

Rolf Kiessling

Rolf Kiessling Karolinska Senior Professor

Senior Professor, Karolinska Institutet

Klas Kärre

Professor, Karolinska Institutet

Michael Kalos

Immunotherapy & T-Cell international KOL

Hans Stråberg

Chairman of the board

Mikael Blomqvist

Co-Founder, Board Member

Fredrik Hansson

Board Member

Sophie Blomqvist

Ragnar Lindqvist

Jan Lundberg

Martin Welschof

Christiane Hanke-Harloff

Anette Brass

Principal Scientist

Athina Totomi

Platform Project Manager

Charlotte Gustafsson

Senior Scientist

Daniela Casarrubea

Dennis Ahlstedt

IT Manager

Hannes Uchtenhagen

Hugh Salter

Chief Scientific Officer

Jacob Michlewicz

Chief Finance Officer

Josefine Dunst

Luke Pase

Chief Technology Officer

Malin Löfdahl

Director of GMP Operations

Mark Farmery

Chief Development Officer

Mattias Persson

Head of Engineering

Mikael Pedin

HR Manager

Miriam Masia-Balague

Niclas Sandberg

Head of Quality Control

Niklas Sjökvist

Head of Production

Reagan Jarvis

Chief Executive Officer, Scientific founder

Rehab Alnabhan

Clinical Science Lead

Richard Samuelson

Lead Software Engineer

Ryan Hill

Chief Information Officer

Sara Horta

Sergey Zelenin

Sheila Forsman

Director of Clinical Development

Shenqiu Wang

Suzana Kovac

Patent Portfolio Manager

Tiphaine Parrot

Viktor Arnkil

Chief Operating Officer

Zahid Bashir

Chief Medical Officer

About

Dysregulated Gene

Driver Mutation

Onco-viral

A*11:01 : G12V

A*11:01 : G12D

A*03:01 : G12V

Other HLAs : G12V

Other HLAs : G12D

Other Mutations

KRAS (Kirsten Rat Sarcoma Viral Oncogene Homolog), plays a crucial role in human cell signaling pathways. KRAS acts as a molecular switch in the MAPK/ERK pathway to regulate cell proliferation, differentiation, and survival. Mutations in KRAS can lead to uncontrolled cell growth, most of which are “Driver Mutations”, causing the development of multiple cancers.

Basic Info

KRAS

A*02 : R175H

The p53 protein plays a pivotal role in regulating cell cycle, DNA repair, and apoptosis to prevent genetic mutations and cancer development. As a transcription factor, it responds to DNA damage by either halting cell division to allow for repair or initiating programmed cell death if the damage is irreparable. Mutations in p53 are found in over half of all human cancers, underscoring its critical role in protecting cells from becoming cancerous.

A*02:01 : P29S

RAC1, a member of the Rho family of GTPases, is a crucial signaling molecule that regulates a wide array of cellular processes including actin cytoskeleton organization, cell growth, migration, and survival. Dysregulation of RAC1 activity is implicated in various pathological conditions, including cancer progression and metastasis.

RAC1

A*02:01

Other HLAs

PRAME (Preferentially Expressed Antigen in Melanoma) is a cancer-testis antigen that plays a role in the regulation of gene expression and immune response modulation. While its precise cellular functions are still being elucidated, PRAME is known to be involved in repressing retinoic acid signaling, a pathway crucial for cell differentiation and growth. This protein is typically expressed at low levels in normal tissues but is upregulated in various malignancies, including melanoma, leukemia, and several solid tumors.

PRAME

MAGE-A4 is a member of the MAGE (Melanoma Antigen Gene), involved in regulating key cellular mechanisms such as apoptosis and cell cycle control, although its exact function remains partially understood. Like its counterparts, MAGE-A4 is predominantly expressed in a wide range of cancers while being minimally present in normal tissues, making it an attractive candidate for cancer diagnostics and targeted therapies. Its involvement in cancer progression and potential role in immune system evasion underscore the therapeutic interest in targeting MAGE-A4 in oncology.

MAGE-A4

A*01:01

MAGE-A3 is a member of the MAGE (Melanoma Antigen Gene), characterized by its selective expression in cancer cells compared to normal tissues. It plays a role in the alteration of apoptotic pathways and immune recognition, contributing to tumor cell survival and proliferation. MAGE-A3 has been extensively studied as a target for cancer vaccines, especially in melanoma and non-small cell lung cancer, due to its immunogenic properties and prevalence in various tumor types.

MAGE-A3

MAGE-A1 is a member of the MAGE (Melanoma Antigen Gene) family, known for its role in immune evasion and cancer progression. This protein is typically silent in most normal adult tissues but becomes aberrantly expressed in a variety of cancers, including melanoma, breast, and lung cancers. MAGE-A1's function in tumorigenesis is still under investigation, but it is believed to modulate key cellular processes like apoptosis and cell cycle regulation. Its cancer-specific expression profile makes MAGE-A1 a promising target for cancer immunotherapy and vaccine development.

MAGE-A1

MAGE-A10 is a member of the MAGE (Melanoma Antigen Gene), known for its cancer-specific expression pattern, particularly in melanoma, lung, and bladder cancers. The protein is implicated in crucial cellular processes that contribute to tumor growth and metastasis. Although the precise mechanisms of MAGE-A10's action are not fully understood, its restricted expression in tumors versus normal tissues positions it as a valuable target for cancer immunotherapy approaches, including vaccines and adoptive T-cell therapies, aimed at eliciting a specific immune response against cancer cells expressing MAGE-A10.

MAGE-A10

NY-ESO-1, also known as Cancer/Testis Antigen 1B (CTAG1B), is a prominent member of the cancer-testis antigen family, characterized by its restricted expression to the testis in normal adult tissues and aberrant expression in a wide range of cancers, including melanoma, sarcoma, bladder, and esophageal cancers. The expression of NY-ESO-1 in tumors but not in most normal tissues makes it an attractive target for therapeutic cancer vaccines, T cell receptor-engineered T cell therapies, and other forms of immunotherapy.

NY-ESO-1

The E7 protein, produced by high-risk HPV strains, acts as a viral oncoprotein by binding to and inactivating the retinoblastoma protein (pRb), a critical tumor suppressor. This interaction releases E2F transcription factors, promoting cell cycle progression and unregulated cell division. E7's disruption of the pRb pathway allows infected cells to evade normal growth controls, contributing significantly to the oncogenic transformation process and the development of cancers associated with HPV infection.

HPV16-E7

About

We are more than 100 scientists, software developers, engineers, manufacturing and quality specialist, and dedicated support and business personnel working out of state-of-the-art facilities in Sweden

Careers

Explore career opportunities at Anocca